VICH GL34: Biologicals: testing for the detection of mycoplasma contamination

<table>
<thead>
<tr>
<th>Draft agreed by IWP</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adoption by CVMP for release for consultation</td>
<td>15 May 2002</td>
</tr>
<tr>
<td>End of consultation (deadline for comments)</td>
<td>30 April 2003</td>
</tr>
<tr>
<td>Adoption by CVMP for release for further(^1) consultation</td>
<td>9 December 2010</td>
</tr>
<tr>
<td>End of consultation (deadline for comments)</td>
<td>31 March 2011</td>
</tr>
<tr>
<td>Draft 2 agreed by VICH Steering Committee</td>
<td>17 November 2011</td>
</tr>
<tr>
<td>Adoption by CVMP for release for consultation</td>
<td>8 December 2011</td>
</tr>
<tr>
<td>End of consultation (deadline for comments)</td>
<td>12 March 2012</td>
</tr>
</tbody>
</table>

Comments should be provided using this template. The completed comments form should be sent to vet-guidelines@ema.europa.eu

---

\(^1\) Draft VICH GL34 was published for consultation first in 2002. Following a 12 months it was agreed to suspend the consultation to wait for the testing of reference strains. The consultation was re-opened to allow submission of any further comments.
VICH GL34 (BIOLOGICALS: MYCOPLASMA)
November 2011
For consultation at Step 4 - Draft 2

TESTING FOR THE DETECTION OF MYCOPLASMA CONTAMINATION

Recommended for Consultation
at Step 4 of the VICH Process
on 17 November 2011
by the VICH Steering Committee

THIS GUIDELINE HAS BEEN DEVELOPED BY THE APPROPRIATE VICH EXPERT WORKING GROUP
AND IS SUBJECT TO CONSULTATION BY THE PARTIES, IN ACCORDANCE WITH THE VICH PROCESS.
AT STEP 7 OF THE PROCESS THE FINAL DRAFT WILL BE RECOMMENDED FOR ADOPTION TO THE
REGULATORY BODIES OF THE EUROPEAN UNION, JAPAN AND THE USA.
1. INTRODUCTION

1.1. Objective of the guideline

This VICH (International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products) guideline is intended to facilitate the harmonized licensing of new products for veterinary use. It is important that biological products for veterinary use are free of contamination with Mycoplasmas to help assure consistency of production and final product safety. Mycoplasma contaminants may be introduced into cell culture and in ovo origin biological products through the master seeds, the master cell seed (stock), starting materials of animal origin, and in processing of biological materials during passage and product assembly. Therefore it is necessary to demonstrate through testing that Mycoplasmas are not present, within the limits of the test, in the final product, working seeds and cells and harvests, and starting materials such as the master seed, master cell seed, and ingredients of animal origin. This guideline establishes stages of manufacture to be tested and test procedures to detect the presence of Mycoplasma contamination. It will provide a unified standard that will facilitate the mutual acceptance of test data by the relevant regulatory authorities. Methods proven equivalent to the guideline method by scientifically accepted criteria could also be acceptable.

1.2. Background

The present methods for testing for Mycoplasma contamination are described in the Japanese “Minimum requirements of biological products for animal use (2002)”, the European Pharmacopoeia (7th Edition, 2011, 2.6.7), and the United States Code of Federal Regulations, Title 9, 113.28. These requirements are all similar in that they require testing for Mycoplasma contamination using a broth and agar technique. The requirements do however differ in the specifics of these broth and agar tests as well as other alternative test methods that are required or approved for use in detecting Mycoplasma contamination.

1.3. Scope of guideline

This guideline describes the manner in which tests conducted to detect the presence of Mycoplasma contamination in cell culture and in ovo origin biological products for veterinary use shall be done to assure the absence of Mycoplasma contamination. Tests on master seeds, master cell seeds (stocks), working seeds and cells, ingredients of animal origin, harvests and live final vaccine and harvests for killed products are included. Bacterial products which grow in the mycoplasma test media and products for which mycoplasma contamination risk has been addressed through a validated mycoplasma inactivation procedure will be considered outside this guideline. The absence of mycoplasma contamination in eggs used for production is controlled by appropriate testing of the flock, which is not covered by this guideline.

1.4. Test Methods

The guideline describes two test methods: 1) expansion in broth culture and detection by colony formation on nutrient agar plates; and 2) expansion in cell culture and characteristic fluorescent staining of DNA (a technique capable of detecting non-cultivable strains).

A third test methodology, nucleic acid amplification (NAT), is acknowledged, but is not included in this guideline. The use of validated NAT techniques is currently approved or under consideration by regulatory authorities for more rapid detection confirmation,
and strain identification. Appropriately validated NAT techniques may be used as an
alternative to the broth/agar culture method and/or the indicator cell culture method
provided the NAT test is shown to be at least equivalent in detection limit to the test
methods in this guideline. A sample that tests positive by NAT may be directly
considered unsuitable for use. If confirmation of the presence of living mycoplasma in
the material under test is needed the broth/agar culture method or the indicator cell
culture method should be used. Evaluation of NAT method use is encouraged in
parallel testing to further develop, compare, and refine the technique for possible
inclusion in future versions of this guideline.

2. GUIDELINE FOR TESTING FOR MYCOPLASMA
CONTAMINATION

2.1. General test procedures for detecting Mycoplasma contamination
The culture method using broth and agar is the fundamental method of Mycoplasma
detection. A solid and liquid media culture method shall be used to test harvests or
final batches of vaccine, and ingredients of animal origin. Master seed, master cell
seed (stock), and working seed and cell lots shall be tested using both a solid and
liquid media culture method and an indicator cell culture method with DNA stain.
Should either method result in a positive test for mycoplasma the sample is considered
positive and is unsuitable for use.

<table>
<thead>
<tr>
<th>Material</th>
<th>Broth &amp; Agar Culture</th>
<th>DNA Stain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Master Seed &amp; Master Cell Seed</td>
<td>Required</td>
<td>Required</td>
</tr>
<tr>
<td>Working Seed &amp; Working Cell Seed</td>
<td>Required</td>
<td>Required</td>
</tr>
<tr>
<td>Ingredient of Animal Origin</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td>Harvest</td>
<td>When testing required</td>
<td></td>
</tr>
<tr>
<td>Final Product</td>
<td>When testing required</td>
<td></td>
</tr>
</tbody>
</table>

1 Excluding eggs
2 Unless a validated mycoplasma inactivation procedure has been applied
3 The competent authorities require testing of different combinations of harvests and final
   product.

2.2. Culture test system validation
The culture method should be carried out to validate the detection limit of a
laboratory’s mycoplasma detection method. A sufficient number of both solid and
liquid media shall be used to insure the growth of a low level of the following 5 strains
of mycoplasmas.

- *Acholeplasma laidlawii*
- *Mycoplasma hyorhinis*
- *Mycoplasma orale*
- *Mycoplasma synoviae*
- *Mycoplasma fermentans*

The species were selected to reflect a range (within a practical number) of antibiotic
sensitivity (to detect inhibition of mycoplasma growth in the assay), fastidiousness,
rapidity of growth, likelihood of being a contaminant, and pathogenicity in avian or
mammalian target species. *Acholeplasma laidlawii* is a common cell culture
contaminant of animal and possibly environmental origin. *Mycoplasma hyorhinis* is
fastidious, a common cell culture contaminant of animal origin, and a mammalian
pathogen. *Mycoplasma orale* is antibiotic sensitive and is a common cell culture
contaminant of human origin. *Mycoplasma synoviae* is fastidious (having a
nicotinamide-adenine-dinucleotide [DPN, NAD] and cysteine requirement) and is an
avian pathogen. *Mycoplasma fermentans* is a slow-growing organism and a common
cell culture contaminant of human origin.

References of the strains used to validate the laboratory mycoplasma contamination
culture test system should be of low passage level (15 or less), and identified relative
to type culture isolates, (see Appendix 3.2 for further information on reference strains).
The reference strains used to validate the culture test system will be appropriate to the
products tested (see table). Validation for *M. synoviae* is required when materials of
avian origin are used at any stage in development and production. Validation for *M.
hyorhinis* and *A. laidlawii* is required when materials of mammalian origin are used at
any stage in development and production. Validation for *M. orale* is required when an
antibiotic has been used at any stage in development and production. Reference
Preparations shall be used to validate each production lot of broth and agar. At least
one reference strain must be used as a control with each test.

**Required Reference Organisms by: product type; test method, and presence of
antibiotics**

<table>
<thead>
<tr>
<th>Vaccine type</th>
<th>Antibiotic content</th>
<th>Test Method</th>
<th>A. laidlawii</th>
<th>M. orale</th>
<th>M. hyorhinis</th>
<th>M. synoviae</th>
<th>M. fermentans</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avian in ovo origin vaccine</td>
<td>Without Antibiotics</td>
<td>Broth/Agar Method</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Avian in ovo origin vaccine</td>
<td>With Antibiotics</td>
<td>Broth/Agar Method</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Avian cell culture origin vaccine</td>
<td>Without Antibiotics</td>
<td>Broth/Agar Method</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Avian cell culture origin vaccine</td>
<td>With Antibiotics</td>
<td>Broth/Agar Method</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Mammalian cell culture origin vaccine</td>
<td>Without Antibiotics</td>
<td>Broth/Agar Method</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Mammalian cell culture origin vaccine</td>
<td>With Antibiotics</td>
<td>Broth/Agar Method</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Vaccine Without Antibiotics</td>
<td>DNA Staining Method</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccine With Antibiotics</td>
<td>DNA Staining Method</td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2.3. Culture Method

2.3.1. Incubation conditions

Incubate the broth culture medium or media in tightly stoppered containers in air. Incubate all agar plates under microaerophilic conditions (nitrogen containing 5-10% CO₂). For the solid medium or media, maintain an atmosphere of adequate humidity to prevent desiccation of the agar surface.

2.3.2. Nutritive properties of a new batch of medium

Each new lot (batch) of medium must be tested for the nutritive properties using references specified above in Section 2.2. Each testing laboratory must determine the inoculum for each of their references that will contain a low level (not more than 100 CFU). Inoculate the solid medium with a low level (not more than 100 CFU) per 60 mm plate and per 100 ml container of broth medium. Use at least one agar plate and broth container for each reference. Incubate the agar and broth media and make subcultures from the broth onto agar at the specified intervals. The agar medium batch complies with the test for nutritive properties if for all the references specified, growth obtained does not differ by a factor greater than 5 from the value calculated with respect to the inoculum. The broth complies if Mycoplasma growth on those agar plates subcultured from the broth is achieved for each reference specified. Media formulations found effective are included in Appendix 3.1 of this guideline.

2.3.3. Inhibitory substances

Carry out the test for nutritive properties in the presence and absence of the material to be tested at the time of prelicense and whenever there is a change in the production method that may affect the detection of mycoplasmas. If growth of the references occurs more than one sub-culture sooner without the test material than with the test material, or if plates directly inoculated with the test material have less than one-fifth of the colonies of those directly inoculated without the test material, the test material contains inhibitory substances. These substances must be neutralized or their effect otherwise countered, e.g., through passage in substrates not containing inhibitors or dilution in a larger volume of medium, before the test for mycoplasma contamination is carried out. For the dilution technique, larger medium volumes may be used or the inoculum volume may be divided among multiple 100 ml flasks. The effectiveness of the neutralization or other process is confirmed by repeating the test for inhibitory substances after neutralization.

2.3.4. Test method

2.3.4.1. The amount of inoculum for each plate of solid medium is 0.2 ml of product to be examined. When an assay for mycoplasma concerns master and working seeds, master and working cells, and ingredients of animal origin a volume of not less than 10 ml of undiluted sample shall be tested in each liquid medium. The volume of final product to be tested in each liquid medium shall be as required by the regulatory authority issuing the marketing authorization. These are currently not less than 1 ml in Japan and the US and not less than 10 ml in the EU. Incubate the agar plates at 35°C to 38°C, microaerophilically, for 10-14 days in an atmosphere of adequate humidity to prevent desiccation of the surface. Incubate the liquid media at 35°C to 38°C in tightly stoppered containers in air for 20-21 days. At the same time incubate
an uninoculated 100 ml portion of each liquid medium and agar plates
as a negative control. If any significant pH change occurs upon the
addition of the product to be examined (this should be determined at
the time of prelicense), the liquid medium shall be restored to its
original pH value by the addition of a solution of either sodium
hydroxide or hydrochloric acid. Between the 2\textsuperscript{nd} and 4\textsuperscript{th} day after
inoculation, subculture each liquid culture by inoculating at least 1
plate of each solid medium with 0.2 ml and incubate them at 35\degree C to
38\degree C microaerophilically for 10-14 days. Repeat the procedure
between the 6\textsuperscript{th} and 8\textsuperscript{th} day, again between the 13\textsuperscript{th} and 15\textsuperscript{th} day, and
again between the 19\textsuperscript{th} and 21\textsuperscript{st} day of the test. Incubate those agar
plates inoculated on day 19, 20, or 21 for 7 days. Observe the liquid
medium or media every 2 or 3 days and if a color change occurs,
subculture. Color change detection requires the addition of phenol red
to the media.

\textbf{2.3.4.2.} If the liquid medium or media shows bacterial or fungal contamination,
repeat the test. If it is not possible to read at least one plate per
inoculation day, the test must be repeated.

\textbf{2.3.4.3.} Include in the test, positive controls prepared by inoculating a low level
(not more than 100 CFU) of at least one of the reference species onto
the agar plates and into the broth medium or media. If the test is run
on a routine basis, the control species should be rotated on a regular
basis. This control shall be used in each test conducted with a
medium that has been validated for nutritive properties using
references determined by the types of products being tested as
specified in Section 2.2 of this guideline.

\textbf{2.3.5. Judgment of the culture method}
At the end of the incubation period, examine all the inoculated solid media
microscopically for the presence of mycoplasma colonies. The product is
negative for Mycoplasma contamination if the growth of typical Mycoplasma
colonies has not occurred on any of the inoculated solid media. If growth of
typical Mycoplasma colonies has occurred on any of the solid media, the test
and sample tested are considered positive for Mycoplasma contamination. The
test is invalid if the positive controls do not show growth of mycoplasma on at
least one subculture plate or the negative controls are positive for mycoplasma
contamination. If either of the controls is invalid the test must be repeated. If
suspect colonies are observed, confirmation of mycoplasma contamination may
be accomplished using an appropriate and validated method.

\textbf{2.4. Indicator cell culture method}
Cell cultures are stained with a fluorescent dye that binds to DNA. Mycoplasmas are
detected by their characteristic particulate or filamentous pattern of fluorescence on
the cell surface, and if contamination is heavy, in the surrounding areas. Mitochondria
in the cytoplasm may be stained, but may be differentiated from mycoplasma.

\textbf{2.4.1. Validation of the indicator cell culture method}
Using a VERO or other equivalent in efficiency indicator cell culture substrate,
validate the procedure using an inoculum not more than 100 CFU or CFU-like
micro-organisms of appropriate references of \textit{M. hyorhinis} and \textit{M. orale}. Both
references must be positive when stained with the DNA stain at the end of the test.

If for viral, etc., suspensions the interpretation of results is affected by cytopathic effects, the virus may be neutralized using a specific antiserum that has no inhibitory effects on mycoplasmas, or an alternative cell culture substrate that does not allow the growth of the virus may be used. To demonstrate the absence of inhibitory effects of serum, carry out the positive control tests in the presence of neutralizing antiserum. Antiserum lots may be qualified once rather than at use.

2.4.2. Test method

2.4.2.1. Seed the indicator cell culture at a suitable density that will yield confluence of the cells after 3 days of growth (example: $2 \times 10^4$ to $2 \times 10^5$ cells per ml, $4 \times 10^3$ to $2.5 \times 10^4$ cells/cm$^2$) in a cell culture vessel of not less than 25 cm$^2$. The indicator cell culture should be sub-cultured without antibiotic prior to use. Inoculate 1 ml of the sample to be examined into the cell culture vessel and incubate at $35^\circ$C to $38^\circ$C.

2.4.2.2. After at least 3 days of incubation and the cells have grown to confluence, make a subculture onto cover slips in suitable containers or on some other surface (chambered slides) suitable for the test procedure. Seed the cells in the second subculture at a low density so that they reach only 50% confluence after 3-5 days of incubation. Complete confluence must be avoided because it impairs visualization of mycoplasmas after staining.

2.4.2.3. Remove medium from cover slips or chambered slides. Rinse the monolayer of indicator cells with phosphate buffered saline (PBS) and then fix with glacial acetic acid/methanol (1 to 3) or some other suitable fixing solution.

2.4.2.4. Remove the fixing solution and discard. Wash the fixing solution with sterile water and dry slides completely if they are to be stained more than one hour later.

2.4.2.5. Add a suitable fluorescent dye that binds to DNA such as bisbenzimide stain (Hoechst compound 33258, bisbenzimidazole, 5 ug/L) and allow to stain for a suitable time.

2.4.2.6. Remove the stain and rinse the monolayer with water. Mount the cover slips if applicable and examine the slides by fluorescence (for bisbenzimide stain use a 330 nm/380 nm excitation filter, LP 440 nm barrier filter) at 400 X magnification or greater.

2.4.2.7. Compare the microscopic appearance of the test cultures with that of the negative and reference controls, examining for extranuclear fluorescence. Mycoplasmas produce pinpoints or filaments over the indicator cell’s cytoplasm. They may also produce pinpoints and filaments in the intercellular spaces. Multiple microscopic fields as validated should be examined.

2.4.3. Judgment of the indicator cell culture method
The product being examined is negative for Mycoplasma contamination if there is no evidence of pinpoints or filaments of extranuclear fluorescence. If the slides inoculated with the product contain evidence of pinpoints or extranuclear fluorescence indicative of Mycoplasma the test and sample tested are considered positive for Mycoplasma contamination. The test is invalid if the positive controls do not show the presence of the appropriate extranuclear fluorescence of the reference organisms or the negative cell controls contain extranuclear fluorescence. If either of the controls is invalid the test must be repeated.
3. APPENDICES

3.1. Regional examples of suitable broth and agar formulations

**9 CFR Mycoplasma Broth**

- Heart Infusion Broth: 62.5 g
- Proteose Peptone #3: 25.0 g
- Yeast Extract: 12.5 ml
- 1% Thallium Acetate: 62.5 ml
- 1% Tetrazolium Chloride: 13.75 ml
- Penicillin (100,000 units/ml): 12.5 ml
- Heat inactivated Horse Serum: 250 ml
- H₂O: 2425 ml

Mix all ingredients well and adjust pH to 7.9 with 10 Normal NaOH. Filter sterilize through a 0.2 μ filter. Dispense into sterile test vessels. Add DPN/L-Cysteine solution before use, 2 ml/100 ml of broth.

**9 CFR Mycoplasma Agar**

- Heart Infusion Agar: 25 g
- Heart Infusion Broth: 10 g
- Proteose Peptone #3: 10 g
- 1% Thallium Acetate: 25 ml
- H₂O: 995 ml
- Heat Inactivated Horse Serum: 126 ml
- Yeast Extract: 5 ml
- Penicillin (100,000 units/ml): 5.2 ml
- DPN/L-Cysteine: 21 ml

Combine heart infusion agar, heart infusion broth, proteose peptone #3, Thallium acetate, and H₂O. Mix and bring to boil, then cool. Adjust the pH to 7.9 with 10 Normal NaOH. Autoclave 20 min. at 121º C. Cool in water bath to 56º C. Aseptically add: horse serum, yeast extract, Penicillin, and DPN/L-Cysteine. Dispense 12 ml into each 15 X 60 mm petri dish.

**DPN/L-Cysteine solution**

- Nicotiamide-adenine-dinucleotide (DPN, NAD): 5 g
- Q.S. with H₂O to 500 ml
- L-Cysteine: 5 g
- Q.S. with H₂O to 500 ml

Mix each chemical separately until dissolved. Mix the two solutions and filter sterilize.

**Japanese Liquid Medium for Mycoplasma**

- Basal Medium
- 50 % w/v Bovine Cardiac Muscle Extract: 100 ml
- Meat Peptone: 10 g
Sodium Chloride    5 g  
Glucose            1 g  
Sodium L-glutamate 0.1 g 
L-arginine hydrochloride 1 g  
H$_2$O QS to 1000 ml 

Filter sterilize through 0.22 μ membrane filter or sterilize at 121º C for 15 min. 
Adjust the pH of the medium after sterilization to 7.2-7.4. 

Additives for 77 ml of the Basal medium; 
Horse Serum 10 ml 
Inactivated Porcine Serum 5 ml 
25 % w/v Fresh Yeast Extract 5 ml 
1 % w/v β-NAD (oxidized) 1 ml 
1 % w/v L-cysteine HCl (1 H$_2$O) 1 ml 
0.2 % w/v phenol red 1 ml 

Previously filter sterilize the additives and aseptically add to the sterilized basal medium. The additives which can be sterilized by high pressure can be autoclaved. 
Penicillin G potassium, 500 units/ml of the medium, or Thallium acetate, 0.02 % w/v, can be added. 

**Japanese Agar Medium for Mycoplasma** 
Basal Medium 78 ml 
Agar 1 g 
Sterilize by autoclaving 121ºC for 15 min. 

Additives: 
Horse Serum 10 ml 
Inactivated Porcine Serum 5 ml 
25 % w/v fresh yeast extract 5 ml 
1 % w/v β-NAD (oxidized) 1 ml 
1 % w/v L-cysteine HCl (1 H$_2$O) 1 ml 
Penicillin G potassium, 500 units per ml of medium, or thallium acetate, 0.02 % w/v can be added. 
Add the additives to basal/agar medium which has been liquefied by heating, and divide into sterile petri dishes, 45-55 mm. Cool and allow to solidify. 

**EP Hayflick media (Recommended media for the general detection of mycoplasmas)** 

**Liquid Medium:** 
Beef Heart Infusion Broth (1) 90 ml 
Horse Serum (unheated) 20 ml 
Yeast Extract (250 g/L) 10 ml 
Phenol Red (0.6 g/L solution) 5 ml 
Penicillin (20,000 I.U. per ml) 0.25 ml 
Deoxyribonucleic acid (2 g/L solution) 1.2 ml 
Adjust to pH 7.8. 

**Solid Medium:**
Prepare as described for the liquid medium above but replace beef heart infusion broth with beef heart infusion agar containing 15 g/L of agar.

**EP Frey media (Recommended Media for the detection of *M. synoviae*)**

**Liquid Medium:**
- Beef Heart Infusion Broth (1)       90 ml
- Essential Vitamins (2)  0.025 ml
- Glucose monohydrate (500 g/L solution)   2 ml
- Swine serum (inactivated at 56°C for 30 min.)   12 ml
- β-Nicotinamide adenine dinucleotide (10 g/L solution)       1 ml
- Cysteine hydrochloride (10 g/L solution)       1 ml
- Phenol Red (0.6 g/L solution)        5 ml
- Penicillin (20,000 I.U. per ml)    0.25 ml

Mix the solutions of β-nicotinamide adenine dinucleotide and cysteine hydrochloride and after 10 minutes, add the other ingredients. Adjust pH to 7.8.

**Solid Medium:**
- Beef Heart Infusion Broth (1)     90 ml
- Ionagar (3)  1.4 g

Adjust pH to 7.8, and sterilize by autoclaving, then add:
- Essential Vitamins (2)  0.025 ml
- Glucose monohydrate (500 g/L solution)   2 ml
- Swine serum (unheated)      12 ml
- β-Nicotinamide adenine dinucleotide (10 g/L solution)       1 ml
- Cysteine hydrochloride (10 g/L solutions)       1 ml
- Phenol Red (0.6 g/L solution)        5 ml
- Penicillin (20,000 I.U. per ml)    0.25 ml

**EP Friis media (Recommended Media for the Detection of Non-avian Mycoplasmas)**

**Liquid Medium:**
- Hank’s Balanced Salt Solution (modified) (4) 800 ml
- H₂O      67 ml
- Brain Heart Infusion (5)    135 ml
- PPLO Broth    248 ml
- Yeast Extract (170 g/L)    60 ml
- Bacitracin  250 mg
- Meticillin  250 mg
- Phenol Red (5 g/L)       4.5 ml
- Horse Serum     165 ml
- Swine Serum     165 ml

Adjust the pH to 7.40-7.45

**Solid Medium:**
- Hank’s Balanced Salt Solution (modified) (4)   200 ml
- DEAE-dextran  200 mg
- Ionagar (3)  15.65 g

Mix well and sterilize by autoclaving. Cool to 100°C. Add this to 1740 ml of the liquid medium described above.
EP Media Sub parts

(1) Beef Heart Infusion Broth

- Beef Heart (for preparation of the infusion) 500 g
- Peptone 10 g
- Sodium Chloride 5 g
- H₂O QS to 1000 ml

Sterilize by autoclaving.

(2) Essential Vitamins

- Biotin 100 mg
- Calcium pantothenate 100 mg
- Choline chloride 100 mg
- Folic acid 100 mg
- i-Insitol 200 mg
- Nicotinamide 100 mg
- Pyridoxal hydrochloride 100 mg
- Riboflavin 10 mg
- Thiamine hydrochloride 100 mg
- H₂O QS to 1000 ml

(3) Ionagar

A highly refined agar for use in microbiology and immunology, prepared by an ion-exchange procedure which results in a product having superior purity, clarity, and gel strength.

- It contains approximately:
  - H₂O 12.2 %
  - Ash 1.5 %
  - Acid insoluble ash 0.2 %
  - Choline 0.0 %
  - Phosphate (calculated as P₂O₅) 0.3 %
  - Total Nitrogen 0.3 %
  - Copper 8 ppm
  - Iron 170 ppm
  - Calcium 0.28 %
  - Magnesium 0.32 %

(4) Hank’s Balanced Salt Solution (modified)

- Sodium chloride 6.4 g
- Potassium chloride 0.32 g
- Magnesium sulphate heptahydrate 0.08 g
- Magnesium chloride hexahydrate 0.08 g
- Calcium chloride, anhydrous 0.112 g
- Disodium hydrogen phosphate dihydrate 0.0596 g
- Potassium dihydrogen phosphate, anhydrous 0.048 g
- H₂O QS to 800 ml

(5) Brain heart infusion

- Calf brain infusion 200 g
- Beef heart infusion 250 g
- Proteose peptone 10 g
- Glucose 2 g
Sodium chloride       5 g
Disodium hydrogen phosphate, anhydrous   2.5 g
H₂O     QS to 1000 ml

(6) PPLO broth
Beef heart infusion    50 g
Peptone    10 g
Sodium chloride      5 g
H₂O     QS to 1000 ml

Disodium hydrogen phosphate, anhydrous   2.5 g
H₂O     QS to 1000 ml

Bisbenzimide stain solution for DNA Staining
Hoechst compound 33258 (bisbenzimidazole), 5 μg per liter of buffered aqueous solution.
Note: The solution should be protected from light.

3.2. Mycoplasma References

Standardization of testing between laboratories and between regions would be enhanced by use of references common within or between regions. This has been shown to be presently impractical due to the difficulty of producing consistent batches of lyophilized references and the shipping issues with frozen references. Therefore, regions or laboratories may use their own references, providing that they are of low passage level (15 or less), identified relative to type culture isolates, stable, and appropriately validated as suitable for use in the context of this guideline. It is strongly recommended to include in the validation of detection limit a comparison to the EDQM reference strains (described below) for international recognition. Regions or laboratories may produce their own validated references, or may acquire commonly available and appropriately validated references, such as the following produced by the EDQM.

The 5 strains of Mycoplasma listed in Section 2.3 were isolated by laboratories of the European Union and donated to the European Directorate for the Quality of Medicines and HealthCare (EDQM). EDQM produced a sufficient quantity of these frozen references, and performed an intra-region EU validation/stability study (C. Milne, A. Daas. Establishment of European Pharmacopoeia Mycoplasma Reference Strains. Pharmeuropa Bio 2006(1):57-72). Completion of further validation studies by the regulatory agencies and the industries in Japan, USA, and Canada confirmed that the strains are very suitable for use in the context of this guideline. (VICH Collaborative Study on the Ph. Eur. Mycoplasma Reference Strains: EDQM Report Compiling and Analysing the Data Set for the VICH Collaborative Study on the European Pharmacopoeia Mycoplasma Reference Strains, EDQM Administrator Representative, C. Milne, 2010.) The BQMEWG commends the Staff at the EDQM for their efforts and perseverance in producing and validating these very excellent references.

For DNA staining validation, the following strains may also prove useful:

M. hyorhinis -- ATCC 29052
M. orale -- ATCC 23714

3.3. Glossary
Batch (lot, serial) of starting material of animal origin
The total quantity of homogenous material (e.g., cells, serum) identified by a unique serial number.

Cell-seed system
A system whereby successive final lots (batches) of a product are manufactured by culture in cells derived from the same master cell seed. A number of containers from the master cell seed are used to prepare a working cell seed.

Cell lines
Cultures of cells >10 passages or subcultures from the tissue of origin and having a high capacity for multiplication in-vitro.

Final product, batch, lot, or serial
A collection of closed, final containers or other final dosage units that are expected to be homogeneous and equivalent with respect to risk of contamination during filling or preparation of the final product. The dosage units are filled, or otherwise prepared, from the same final bulk product, freeze-dried together (if applicable) and closed in one continuous working session. They bear a distinctive number or code identifying the final lot (batch, serial). Where a final bulk product is filled and/or freeze-dried on several separate sessions, there results a related set of final lots (batches, serials) that are usually identified by the use of a common part in the distinctive number or code; these related final lots (batches, serials) are sometimes referred to as sub-batches, subserials, sub-lots or filling lots. For the purposes of mycoplasma testing, a single sub-batch may be considered representative of the batch.

Harvests
Material derived on one or more occasions from a single production culture inoculated with the same working seed lot (single harvest) or pooled material containing a single strain or type of micro-organism or antigen and derived from a number of eggs, cell culture containers, etc. that are processed at the same time (monovalent pooled harvest).

Master cell seed (stock)
A collection of aliquots of cells (primary or cell line) of a single passage level for use in the preparation of the product, distributed into containers in a single operation, processed together and stored in such a manner as to ensure uniformity and stability and to prevent contamination. Master cell seed is usually stored at temperatures of -70°C or lower.

Master seed
A collection of closed containers of a culture of micro-organisms of a single passage level used for the production of all batches of a designated veterinary biological product, distributed from a single bulk into containers and processed together in a single operation in such a manner as to ensure uniformity and stability and to prevent contamination.

Microaerophilic condition
A nitrogen atmosphere containing 5-10% carbon dioxide and sufficient humidity to prevent drying of the agar plates.
Passage

One transfer of cells or microorganisms followed by the normally used incubation period for the cell or microorganism concerned.

Primary cell cultures

Primary cell cultures are cultures of cells essentially unchanged from those in the animal tissues from which they have been prepared and being no more than 10 in-vitro passages to the test level from the initial preparation from the animal tissue. The first in-vitro cultivation is regarded as the first passage of the cells.

Seed-lot system:

A system in which successive batches of a product are derived from the same master seed virus. For routine production, a working seed virus may be prepared from the master seed virus.

Working cell seed (stock)

A collection of aliquots of cells derived from the master cell seed and at the passage level used in the preparation of production cell cultures. The working cell seed is distributed into containers, processed and stored as described for master cell seed. The term includes production cell seed.

Working References

A passage of the Reference strains of Mycoplasma produced in the testing laboratory for use as controls to satisfy the reference requirements specified in this document.

Working seed

A collection of aliquots of a microorganism derived from the master seed virus and at the passage level used in the preparation of product. Working seed virus is distributed into containers and stored as described for master seed virus. The term includes production seed.